Corcept Therapeutics Incorporated 10,000,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • January 21st, 2011 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom Stifel, Nicolaus & Company, Incorporated and Leerink Swann LLC are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares (the “ Firm Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 1,500,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
